Sunesis Pharmaceuticals (NASDAQ: SNSS) spotted trading -67.30% off 52-week high price. On the other end, the stock has been noted 325.05% away from the low price over the last 52-weeks. The stock changed 4.95% to recent value of $0.85. The stock transacted 1962465 shares during most recent day however it has an average volume of 1069.25K shares. The company has 66.99M of outstanding shares and 66.99M shares were floated in the market.
Sunesis Pharmaceuticals (NASDAQ: SNSS) reported that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series F Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the proposed offerings may be completed, or as to the actual size or terms of the offerings. Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offerings to fund ongoing development of vecabrutinib, ongoing research and development, and general corporate purposes.
Wells Fargo Securities, LLC and Oppenheimer & Co. Inc. are acting as joint book-running managers in these proposed offerings.
Its earnings per share (EPS) expected to touch remained 48.30% for this year .
According to the most recent quarter its current ratio was 2.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 20.64% from the mean of 20 days, -6.06% from mean of 50 days SMA and performed -14.26% from mean of 200 days price. Company’s performance for the week was 30.78%, 21.15% for month and YTD performance remained 104.50%.